Fifteen cancer patients receiving cisplatin-containing chemotherapy participated in two antiemetic studies. In Study 1 they received standard antiemetics in low doses on demand, and in Study 2 the same patients participated in an open randomized cross-over study between metoclopramide 1 and 2 mg/kg i.v.×5.
Serum metoclopramide was determined by HPLC. Self-reporting of nausea using a visual analogue scale (VAS) was compared with observer rated scores. Tolerability and volume vomited were assessed by nurse observers.
The biological half-life of metoclopramide was 9.9 h, the volume of distribution was 9.9 l/kg and the clearance was 0.68 l/h/kg. The pharmacokinetics of high dose metoclopramide was linear in the range 0.15–2 mg/kg×5, with very little accumulation.
Compared to standard antiemetics, both high dose regimens of metoclopramide had a significant effect on nausea, but no effect on the volume vomited. Self reports of nausea were significantly correlated with observer rated values. Tolerance of high dose metoclopramide was good except in 3 patients who left the study because of restlessness and trismus.
It is concluded that high dose metoclopramide probably can be administered for several consecutive days without appreciable accumulation of the drug. Self-reporting of nausea by patients on VAS is a simple and feasible method of evaluation. The finding that metoclopramide affects nausea but not vomiting supports the hypothesis that nausea and vomiting should be evaluated separately in assessing antiemetic efficacy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Borison HL, Brand ED, Orkand RK (1958) Emetic action of nitrogen mustad (metoclorethamine hydrochloride) in dogs and cats. Am J Physiol 192: 410–416
Gylys JA, Doran KM, Buyniski JP (1979) Antagonism of cisplatin-induced emesis in the dog. Res Commun Chem Pathol Pharmacol 23: 61–68
McCarthy LE, Borison HL (1984) Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats. Cancer Treat Rep 68: 401–404
Schulze-Delrieu K (1979) Metoclopramide. Gastroenterology 77: 768–779
Gralla RJ, Squillante AE, Steele N, Kelsen DP, Young CW (1980) Phase 1 intravenous trial of the antiemetic metoclopramide in patients receiving cis-platinum (DDP). Proc Am Soc Clin Oncol C-122
Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Bordin LA, Braun TJ, Young CW (1981) Antiemetic efficacy of high-dose metoclopramide: Randomised trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305: 905–909
Tyson LB, Gralla RJ, Clark RA, Kris MG (1983) Combination antiemetic trials with metoclopramide (MCP). Proc. Am Soc Clin Oncol C-356
Frustraci S, Tumolo S, Tirelli U, Galligioni E, Figoli F, Franchin G, Boz G, Grigoletto E (1983) High dose metoclopramide (MCP) versus dexamethasone (DeX) in the prevention of cisplatin (DDP) induced vomiting: A cross-over randomized study. Proc Am Soc Clin Oncol C-338
Gralla RJ, Tyson LB, Clark RA, Bordin LA, Kelsen DP, Kalman LB (1982) Antiemetic trials with high dose metoclopramide: Superiority over THC, and preservation of efficacy in subsequent chemotherapy courses. Proc Am Soc Clin Oncol C-222
Allan S, Cornbleet M, Warrington P, Leonard R, Smyth J (1984) Trial of dexamethasone (D) and high dose metoclopramide (HDM) versus HDM in cis-platinum (CP)-induced emesis. Proc Am Soc Clin Oncol C-345
Deppe G, Smith P, Wall D, Malviya VK (1984) A comparison of the antiemetic effects of low dose (L) and high dose (H) metoclopramide in gynocologic cancer patients receiving cisplatin. Proc Am Soc Clin Oncol C-365
Morrow GR (1984) The assessment of nausea and vomiting. (Past problems, current issues and suggestions for future research.) Cancer 53: 2267–2278
Saller R, Hellenbrecht D, Briemann L, Hellstern A, Hess H, Mitrou P, Hodgson M, Achtert G, Brockmann P, Hausleiter HJ (1985) Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis. Clin Pharmacol Ther 37: 43–47
Taylor WB, Proctor SJ, Bateman DN (1984) Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting. Br J Clin Pharmacol 18: 679–684
Bateman DN (1983) Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet 8: 523–529
Taylor WB, Bateman DN (1983) High dose metoclopramide-preliminary pharmacokinetic studies. Br J Clin Pharmacol 16: 341–342
Teng L, Bruce RB, Dunning LK (1977) Metoclopramide metabolism and determination by high-pressure liquid chromatography. J Pharm Sci 66: 1615–1618
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications Inc. Illinois, USA, first edn
Baker RJ, Nelder JA (1978) The GLIM system. Release 3. Generalised Linear Interactive Modelling. Numerical Algorithms Group, Royal Statistical Society. Oxford
Gralla RJ, Braun TJ, Squillante A, Steele N, Kelsen DP, Young CW (1981) Metoclopramide: Initial clinical studies of high-dosage regimens in cisplatin-induced emesis. In: Poste DS, Penta JS, Bruno S (eds) Treatment of cancer chemotherapy-induced nausea and vomiting. Masson, New York, pp 167–176
Borison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5: 192–230
Roos IA, Fairlie DP, Whitehouse MW (1981) A peculiar toxicity manifested by platinum (II) amines in rats: Gastric distension after intraperitoneal administration. Chem Biol Interact 35: 111–117
Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS (1976) Metoclopramide: A review of its pharmacological and clinical use. Drugs 12: 81–131
Chang JC (1981) Nausea and vomiting in cancer patients: An expression of psychocological mechanisms. Psychosomatics 22: 707–709
Huskisson EC (1983) Visual analogue scales. In: Melzack R (ed) Pain measurements and assessment. Raven Press, New York, pp 33–37
Fetting JH, Grochow LB, Folstein MF, Ettinger DS, Colvin M (1982) The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66: 1487–1493
Graffner C, Lagerström P-O, Lundborg O (1979) Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Br J Clin Pharmacol 8: 469–474
Bateman DN, Kahn C, Davis DS (1980) The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol 9: 371–377
Ross-Lee LM, Eadie MJ, Hooper WD, Bochner F (1981) Single-dose pharmacokinetics of metoclopramide. Eur J Clin Pharmacol 20: 465–471
Bateman DN, Proctor SJ, Rawlins MD, Taylor WB (1983) Kinetics and efficacy of high dose metoclopramide used in the prevention of cytotoxic induced nausea and vomiting. Br J Pharmacol 80: 490P
Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC (1983) Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 25: 451–494
Gibaldi M (1969) Effect of mode of administration on drug distribution in a two-compartment open system. J Pharm Sci 58: 327–331
McGovern E, Bryson SM, Kelman AW, Whyte KF, Whiting B, Addis GJ (1983) The pharmacokinetics of high dose metoclopramide in patients with bronchial carcinoma. J Pharm Pharmacol 35: 93P
McDermed JE, Waugh WJ, Strum SB (1984) A preliminary pharmacokinetic (PK) evaluation of high dose (HD) metoclopramide (MCP) in patients (PTS) receiving cisplatinum (DDP) chemotherapy (CT). Proc Am Soc Clin Oncol C-409
About this article
Cite this article
Havsteen, H., Nielsen, H. & Kjaer, M. Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens. Eur J Clin Pharmacol 31, 33–40 (1986). https://doi.org/10.1007/BF00870982
- high dose
- antiemetic efficacy
- cancer patients